A late relapse thymoma and pure red cell aplasia case with an over 5 years of clinical response under everolimus
ANTI-CANCER DRUGS, cilt.34, sa.10, ss.1193-1195, 2023 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 34 Sayı: 10
- Basım Tarihi: 2023
- Doi Numarası: 10.1097/cad.0000000000001504
- Dergi Adı: ANTI-CANCER DRUGS
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE, Veterinary Science Database
- Sayfa Sayıları: ss.1193-1195
- Anahtar Kelimeler: everolimus, long-term clinical benefit, thymoma, THYMIC CARCINOMA, PHASE-II, CHEMOTHERAPY, MALIGNANCIES, ONCOLOGY
- Ankara Üniversitesi Adresli: Evet
Özet
Although several agents showed some clinical activity in patients with recurrent thymoma, there is no standard treatment option. Here, we report a late relapse thymoma and pure red cell aplasia case, responsive to everolimus with over 5 years of clinical benefit following multiple lines of treatment. Everolimus controlled the rapidly progressive disease in our patient without significant toxicity.